From: Modeling the public health impact of malaria vaccines for developers and policymakers
% decrease in public health impact (events averted) | % increase in cost/event averted | Increase in cost/case averted 2011 USD, undiscounted (discounted) | |
---|---|---|---|
Uncomplicated cases | |||
Efficacy | 13 | 16 | 3 (2) |
Transmission | 21 | 26 | 5 (3) |
Both | 33 | 47 | 9 (5) |
Severe cases | |||
Efficacy | 14 | 16 | 91 (50) |
Transmission | 21 | 26 | 145 (80) |
Both | 31 | 46 | 258 (142) |
Deaths | |||
Efficacy | 19 | 24 | 650 (358) |
Transmission | 21 | 26 | 711 (392) |
Both | 36 | 57 | 1528 (842) |
DALYs | |||
Efficacy | 18 | 22 | 23 (12) |
Transmission | 21 | 26 | 27 (14) |
Both | 35 | 54 | 55 (30) |